Low-dose Gonal-f® in Ovulation Induction (LoGo)
A Multi-Centre, Two-Arm, Interventional, Phase IV Study to Evaluate Tailoring of Recombinant FSH Treatment in Subjects With Chronic Anovulation Using the Gonal-f® Prefilled Pen in Women Undergoing Ovulation Induction
Sponsor: Merck KGaA, Darmstadt, Germany
Terminated
Study was terminated because of delays in sourcing replacement Investigational Medicinal Product for the study due to manufacturing delays.
Other terminated trials from Merck KGaA, Darmstadt, Germany
This PHASE4 trial investigates Infertility and Monofollicular Development and is currently terminated or withdrawn. Merck KGaA, Darmstadt, Germany leads this study, which shows 11 recorded versions since 2013 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE4
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE4
▶ Show 6 earlier versions
-
Jan 2019 — Nov 2020 [monthly]
Terminated PHASE4
-
Jun 2018 — Jan 2019 [monthly]
Terminated PHASE4
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE4
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE4
-
Feb 2017 — Aug 2017 [monthly]
Terminated PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE4
First recorded
Jul 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck KGaA, Darmstadt, Germany
For direct contact, visit the study record on ClinicalTrials.gov .